Fox News AI Newsletter: 'America's great industrial comeback'
-- Vance knocks globalization's 'cheap labor' and lauds 'America's great industrial comeback' at AI summit-- Home robot automates household chores like Rosie from 'The Jetsons'-- AI dashcams enhance trucker safety while raising privacy concerns-- Getting divorced? Artificial intelligence deepfakes could cost you in court
'INDUSTRIAL COMEBACK': Vice President JD Vance knocked recent globalization efforts that use "cheap labor as a crutch" while simultaneously hampering innovation on the global scale during a Tuesday tech and artificial intelligence speech.
NO MORE CHORES: Developed by the artificial intelligence company 1X, NEO Gamma isn't your clunky, metallic automaton. It is designed to be a helpful, almost human-like assistant.
AI DASHCAM DILEMMA: The trucking industry is in the midst of a technological revolution, thanks to the arrival of artificial intelligence-powered dashcams. These innovative devices promise to make roads safer and operations more efficient, but they also raise some important questions about privacy.
REAL 'THREAT': Americans looking to settle a divorce and obtain custody of their children could rack up unforeseen court costs by trying to disprove artificial intelligence (AI)-generated deepfake videos, photographs and documents, according to a leading family law attorney.
FOLLOW FOX NEWS ON SOCIAL MEDIA
FacebookInstagramYouTubeTwitterLinkedIn
SIGN UP FOR OUR OTHER NEWSLETTERS
Fox News FirstFox News OpinionFox News LifestyleFox News Health
DOWNLOAD OUR APPS
Fox NewsFox BusinessFox WeatherFox SportsTubi
WATCH FOX NEWS ONLINE
STREAM FOX NATION
Stay up to date on the latest AI technology advancements and learn about the challenges and opportunities AI presents now and for the future with Fox News here.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Axios
23 minutes ago
- Axios
Trump says Social Security is stronger, but signs of trouble at the agency mount
President Trump is expected to sign a proclamation today celebrating the 90th anniversary of Social Security and promoting the program's improvements under his leadership, a White House official confirms to Axios. Why it matters: Reports from inside the agency tell a different story; Social Security advocates are questioning whether the administration may be weighing changes to the popular program that would be harmful to its long-term success. Social Security "looks more threatened than ever," is how the AP puts it. Tens of millions of Americans rely on Social Security benefits to make ends meet, and polling suggests it is the most popular government policy. Where it stands: The Social Security Administration, the agency that oversees the program, lost thousands of employees this year, including senior executives with deep understanding of how the program works. The field offices, Social Security's "front door," where the public goes for help, signing up for benefits, getting cards, etc., are down about 20% of staff this year, taking into account folks who've been transferred to work phone lines, per an Axios tally. Workers there are buckling under the strain of understaffing, they told Axios. The administration has a much more upbeat view. "President Donald J. Trump repeatedly promised to preserve and protect Social Security for every eligible American — and he has unquestionably delivered," the White House said in a press release Thursday. "By massively improving the customer service experience through technological improvements, preventing illegal aliens from accessing benefits, and delivering no taxes on Social Security through the One Big Beautiful Bill – President Trump has Made Social Security Great Again," White House spokeswoman Liz Huston said in a statement. Zoom in: While the White House and president have make supportive statements, there's been a drip of comments from administration officials and nominees suggesting that Social Security should be privatized and calling it a Ponzi scheme — a longstanding way conservatives have criticized the program. Meanwhile: The tax cut for seniors in the "big, beautiful bill" will likely speed up the date when the program's trust funds will be depleted, according to the agency's actuary. That follows bipartisan legislation last year that also sped up that process. The depletion in the Social Security trust funds would lead to a cut in benefits — but not the end of the program. The other side: Social Security Administration commissioner Frank Bisignano has been touting improvements to customer service. "Since taking office, I have focused on modernizing operations; investing in our workforce; eliminating fraud, waste, and abuse; and improving how we serve the public, whether online, over the phone, or in person," he wrote in a column for Fox News on Thursday. Bisignano has removed many of the stats that the agency used to display on its website to track customer service, per The Washington Post. But according to data the agency has released this year, wait times for those trying to reach Social Security by phone have declined this year. Critics say that's a misleading measure — since improvements to how the phone lines work were put in place by the prior administration.
TechCrunch
23 minutes ago
- TechCrunch
Cohere hits a $6.8B valuation as investors AMD, Nvidia, and Salesforce double down
Cohere on Thursday announced that it had raised an oversubscribed $500 million round, bringing its valuation to $6.8 billion. This is up from the $5.5 billion valuation it landed a little over a year ago when it raised its previous round, also $500 million. Toronto-headquartered Cohere was one of the first breakout LLM model makers, founded in 2019 by co-founder Aidan Gomez, one of the authors of the 'Attention is all You Need' paper that became the foundation of modern AI. But it has been a sleeper entrant in the AI model wars of late, dominated these days by OpenAI, Anthropic, and Meta. Its market proposition, however, has always been to offer secure LLMs specifically geared for enterprise use, not for consumers. To that end, it's landed partnerships with some of the biggest names in enterprise tech including Oracle, Dell, Bell, Fujitsu, LG's consulting service CNS, and SAP, as well as some big enterprise names like RBC, and a new investor in this round: Healthcare of Ontario Pension Plan. Its press release even includes a jibe that Cohere 'represents a security-first category of enterprise AI that is simply not being met by repurposed consumer models.' Still, as TechCrunch reported, Cohere is not above the AI talent poaching frenzy that has engulfed the other AI companies. It just nabbed long-time Meta research head Joelle Pineau to be its chief AI officer. It also hired a new CFO, Francois Chadwick, away from his consulting gig at KPMG. He had worked in finance at Uber and as CFO at Shield AI. The new round was led by Radical Ventures and Inovia Capital. Radical has backed companies like Fei-Fei Li's World Labs as well as names like Hebbia and Writer. Innovia is a known Canadian venture firm (Poolside, Neo4j). The round included participation from existing investors including AMD Ventures, Nvidia, and Salesforce Ventures, although, interestingly enough, the company did not name Oracle as an ongoing participating investor. (We've asked Cohere about this.) Techcrunch event Tech and VC heavyweights join the Disrupt 2025 agenda Netflix, ElevenLabs, Wayve, Sequoia Capital, Elad Gil — just a few of the heavy hitters joining the Disrupt 2025 agenda. They're here to deliver the insights that fuel startup growth and sharpen your edge. Don't miss the 20th anniversary of TechCrunch Disrupt, and a chance to learn from the top voices in tech — grab your ticket now and save up to $600+ before prices rise. Tech and VC heavyweights join the Disrupt 2025 agenda Netflix, ElevenLabs, Wayve, Sequoia Capital — just a few of the heavy hitters joining the Disrupt 2025 agenda. They're here to deliver the insights that fuel startup growth and sharpen your edge. Don't miss the 20th anniversary of TechCrunch Disrupt, and a chance to learn from the top voices in tech — grab your ticket now and save up to $675 before prices rise. San Francisco | REGISTER NOW Oracle backed Cohere in 2023, but the database giant has more recently tied its fortunes more closely to OpenAI, particularly as part of the massive data center building project known as Stargate.
Fast Company
23 minutes ago
- Fast Company
Eli Lilly signs $1.3 billion deal with Superluminal to use AI to make obesity medicines
Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases. Lilly currently dominates the obesity treatment market, which is estimated to be worth $150 billion by the next decade, and is trying to strengthen its foothold in the space through the development of next-generation drugs, acquisitions and partnerships. The deal gives Lilly access to Superluminal's proprietary artificial-intelligence-driven platform to rapidly discover potential drug candidates targeting G-protein-coupled receptors (GPCR)—a class of proteins that can influence a range of physiological processes including metabolism, cell growth and immune responses—the drug developer said on Thursday. In a similar move, Danish rival Novo Nordisk struck a $2.2 billion deal with U.S. biotech Septerna in May to develop oral small-molecule medicines targeting GPCRs for obesity and other cardiometabolic diseases. Lilly has been capitalizing on the overwhelming popularity of the GLP-1 class of medicines, which includes its blockbuster drug Zepbound as well as Novo's Wegovy. It is also developing a keenly watched oral GLP-1 drug, orforglipron, which has failed to meet investors' lofty expectations. The drugmaker teamed up with Hong Kong-listed biotech Laekna last year to develop an experimental obesity drug that aims to help patients lose weight while preserving muscle. Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's platform, the drug developer said. As part of the deal, Superluminal is eligible to receive upfront and milestone payments, an equity investment as well as tiered royalties on net sales, the company said. Boston-based startup Superluminal is developing a wholly owned lead candidate targeting a protein called melanocortin 4 receptor to treat certain rare, genetic forms of obesity and is expected to begin human trials next year. The lead candidate is not part of the deal with Lilly. Superluminal is backed by investors including RA Capital Management, Insight Partners and NVentures, NVIDIA's venture capital arm.
